Literature DB >> 27119565

Clinicopathological Factors Associated with Recurrence and Prognosis after R0 Resection for Stage IV Colorectal Cancer with Peritoneal Metastasis.

Harunobu Sato1, Kenjiro Kotake, Kenichi Sugihara, Hiroshi Takahashi, Kotaro Maeda, Ichiro Uyama.   

Abstract

BACKGROUND/AIMS: Peritoneal metastasis (PM) is a well-known predictor of poor prognosis. This study aims at identifying factors affecting recurrence and prognosis after R0 resection for colorectal cancer (CRC) with synchronous PM.
METHODS: A multi-institutional, retrospective analysis of 172 patients with R0 surgery for CRC with PM was conducted. Clinicopathological variables were analyzed for their significance in contributing toward recurrence and prognosis.
RESULTS: Lymph node (LN) metastasis was an independent factor affecting recurrence as indicated by logistic regression analyses. The following factors were independent predictors of poor prognostic using the Cox proportional hazard model: LN metastasis, no postoperative adjuvant chemotherapy, five or fewer dissected LNs, and preoperative high serum carbohydrate antigen 19-9 levels. Of the patients undergoing postoperative adjuvant chemotherapy, no significant differences were observed in recurrence rate and disease-free interval between those with intensive adjuvant chemotherapy and those with non-intensive chemotherapy. After R0 surgery for PM, 90 patients (76.3%) experienced recurrence by 18 months, and hematogenous recurrence occurred significantly more often than peritoneal recurrence.
CONCLUSION: Harvesting of more than 5 LNs and administration of postoperative adjuvant chemotherapy after R0 surgery are recommended for prognosis improvement. Intensive follow-up should be performed within 18 months after R0 surgery for CRC with synchronous PM.
© 2016 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27119565     DOI: 10.1159/000444097

Source DB:  PubMed          Journal:  Dig Surg        ISSN: 0253-4886            Impact factor:   2.588


  9 in total

Review 1.  [Hyperthermic intraperitoneal chemotherapy].

Authors:  H Leebmann; P Piso
Journal:  Chirurg       Date:  2019-07       Impact factor: 0.955

Review 2.  Metastatic Colorectal Cancer to the Peritoneum: Current Treatment Options.

Authors:  Nikolaos Vassos; Pompiliu Piso
Journal:  Curr Treat Options Oncol       Date:  2018-09-01

3.  Factors Prognostic for Peritoneal Metastases from Colorectal Cancer Treated with Surgery.

Authors:  Chao Chen; Jian Wang; Yamei Zhao; Xiaoxu Ge; Zhanhuai Wang; Shaojun Yu; Yongmao Song; Kefeng Ding; Suzhan Zhang; Shu Zheng; Lifeng Sun
Journal:  Cancer Manag Res       Date:  2020-10-27       Impact factor: 3.989

4.  High expression of COL10A1 is associated with poor prognosis in colorectal cancer.

Authors:  Haipeng Huang; Tingting Li; Gengtai Ye; Liying Zhao; Zhenzhan Zhang; Debin Mo; Yiming Wang; Ce Zhang; Haijun Deng; Guoxin Li; Hao Liu
Journal:  Onco Targets Ther       Date:  2018-03-20       Impact factor: 4.147

5.  Adjuvant chemotherapy improves prognosis of resectable stage IV colorectal cancer: a comparative study using inverse probability of treatment weighting.

Authors:  Hiroaki Nozawa; Hirotoshi Takiyama; Kiyoshi Hasegawa; Kazushige Kawai; Keisuke Hata; Toshiaki Tanaka; Takeshi Nishikawa; Kazuhito Sasaki; Manabu Kaneko; Koji Murono; Shigenobu Emoto; Hirofumi Sonoda; Jun Nakajima
Journal:  Ther Adv Med Oncol       Date:  2019-04-16       Impact factor: 8.168

6.  Discovery of core genes in colorectal cancer by weighted gene co-expression network analysis.

Authors:  Cun Liao; Xue Huang; Yizhen Gong; Qiuning Lin
Journal:  Oncol Lett       Date:  2019-07-11       Impact factor: 2.967

7.  COL10A1 allows stratification of invasiveness of colon cancer and associates to extracellular matrix and immune cell enrichment in the tumor parenchyma.

Authors:  Ulf D Kahlert; Wenjie Shi; Marco Strecker; Lorenz A Scherpinski; Thomas Wartmann; Maximilian Dölling; Aristotelis Perrakis; Borna Relja; Miriam Mengoni; Andreas Braun; Roland S Croner
Journal:  Front Oncol       Date:  2022-10-04       Impact factor: 5.738

8.  Development and Validation of a Prognostic Nomogram for Colorectal Cancer Patients With Synchronous Peritoneal Metastasis.

Authors:  Zifeng Yang; Yong Li; Xiusen Qin; Zejian Lv; Huaiming Wang; Deqing Wu; Zixu Yuan; Hui Wang
Journal:  Front Oncol       Date:  2021-07-01       Impact factor: 6.244

9.  miR-133b suppresses metastasis by targeting HOXA9 in human colorectal cancer.

Authors:  Xiao Wang; Juyuan Bu; Xingwei Liu; Wenfeng Wang; Weihua Mai; Baojun Lv; Jinlin Zou; Xiangqiong Mo; Xiaoling Li; Jingyu Wang; Bin Niu; Yunping Fan; Bingzong Hou
Journal:  Oncotarget       Date:  2017-07-12
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.